PD98059

Catalog No.S1177

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Cited by 128 Publications

Cell Stem Cell, 2017, 20(3):329-344

PubMed: 28089908 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Emerg Microbes Infect, 2019, 8(1):934-945

PubMed: 31237474 ( click the link to review the publication )

J Clin Med, 2019, 8(6)

PubMed: 31238539 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):75

PubMed: 31307477 ( click the link to review the publication )

Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

J Cell Physiol, 2019, 234(6):8846-8861

PubMed: 30317597 ( click the link to review the publication )

Inflammopharmacology, 2019, 27(3):561-571

PubMed: 30251233 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:2653-2661

PubMed: 31114328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 116:109032

PubMed: 31163381 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):12500-12507

PubMed: 30834595 ( click the link to review the publication )

Life Sci, 2019, 229:1-12

PubMed: 30910647 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Free Radic Res, 2019, 53(3):348-358

PubMed: 30773942 ( click the link to review the publication )

Environ Toxicol, 2019, 34(6):679-688

PubMed: 30801954 ( click the link to review the publication )

Am J Reprod Immunol, 2019, 81(1):e13073

PubMed: 30461130 ( click the link to review the publication )

Am J Chin Med, 2019, 913-931

PubMed: 31096773 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1140

PubMed: 30442927 ( click the link to review the publication )

Br J Cancer, 2018, 119(9):1094-1105

PubMed: 30401978 ( click the link to review the publication )
Biochim Biophys Acta Mol Cell Res, 2018, 1865(1):57-66

PubMed: 28964848 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

Inflammopharmacology, 2018, 10.1007/s10787-018-0492-y

PubMed: 29748880 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:320-325

PubMed: 29864620 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):300-313

PubMed: 28569433 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(2):109-117

PubMed: 25588050 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(4):1291-1295

PubMed: 29412164 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(3):155-165

PubMed: 29441602 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):7443-7449

PubMed: 29731895 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8442-8446

PubMed: 29805580 ( click the link to review the publication )

In Vivo, 2018, 32(3):549-554

PubMed: 29695559 ( click the link to review the publication )

In Vivo, 2018, 32(6):1361-1368

PubMed: 30348689 ( click the link to review the publication )

Cancer Lett, 2017, 395:31-44

PubMed: 28268166 ( click the link to review the publication )

Cancer Lett, 2017, 401:1-10

PubMed: 28483515 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 41(5):1957-1969

PubMed: 28391263 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(9):1694-1704

PubMed: 28674151 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1037-1044

PubMed: 28292012 ( click the link to review the publication )

Biomed Pharmacother, 2017, 87:332-341

PubMed: 28064106 ( click the link to review the publication )

Exp Cell Res, 2017, 360(2):281-291

PubMed: 28919123 ( click the link to review the publication )

Chem Biol Interact, 2017, 270:1-8

PubMed: 28390675 ( click the link to review the publication )

Am J Transl Res, 2017, 9(6):2878-2890

PubMed: 28670376 ( click the link to review the publication )

Dev Comp Immunol, 2017, 76:392-402

PubMed: 28713009 ( click the link to review the publication )
Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1036-1044

PubMed: 28000898 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

DNA Cell Biol, 2017, 36(11):1029-1038

PubMed: 28945461 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 492(2):206-211

PubMed: 28821432 ( click the link to review the publication )

Food Nutr Res, 2017, 61(1):1368321

PubMed: 28970779 ( click the link to review the publication )

Microb Pathog, 2017, 10.1016/j.micpath

PubMed: 28131949 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:5985703

PubMed: 28167972 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1445-1450

PubMed: 29067463 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1417-1424

PubMed: 28627644 ( click the link to review the publication )

Poult Sci, 2017, 96(9):3043-3051

PubMed: 28431078 ( click the link to review the publication )

Oncotarget, 2017, 8(15):24237-24249

PubMed: 27458161 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(4):524-34

PubMed: 26166769 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):640-50

PubMed: 27593484 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Mol Oncol, 2016, 10(6):775-88

PubMed: 26842883 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:2572175

PubMed: 26962394 ( click the link to review the publication )

J Ethnopharmacol, 2016, 193:293-302

PubMed: 27553977 ( click the link to review the publication )

Prostate, 2016, 76(3):273-85

PubMed: 26499308 ( click the link to review the publication )

Exp Cell Res, 2016, 345(1):82-92

PubMed: 27237094 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 80:132-142

PubMed: 27702651 ( click the link to review the publication )
Cell Immunol, 2016, 310:63-70

PubMed: 27687530 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1635-44

PubMed: 26961889 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(2):330-7

PubMed: 27107695 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Sci Rep, 2016, 6:30121

PubMed: 27444207 ( click the link to review the publication )

Toxicol Res (Camb), 2016, 5(6):1573-1584

PubMed: 30090458 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10257-67

PubMed: 26831668 ( click the link to review the publication )

Tumour Biol, 2016, 37(3):3727-38

PubMed: 26468015 ( click the link to review the publication )

Pflugers Arch, 2016, 468(11-12):2041-2051

PubMed: 27592222 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms9390

PubMed: 26399630 ( click the link to review the publication )

J Transl Med, 2015, 13(1):42

PubMed: 25638174 ( click the link to review the publication )

Cytokine, 2015, 17:139-144

PubMed: ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22830

PubMed: 25731708 ( click the link to review the publication )

Exp Biol Med, 2015, 10.1177/1535370215576312

PubMed: 25767191 ( click the link to review the publication )

Acta Biochim Biophys Sin, 2015, 47(7), 1–9

PubMed: 26071572 ( click the link to review the publication )

Tissue Cell, 2015, 47(3):301-10

PubMed: 25958163 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1187

PubMed: 24743742 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Cell Microbiol, 2014, 16(9):1441-55

PubMed: 24779413 ( click the link to review the publication )

Biomed Pharmacother, 2014, 68(8):1037-43

PubMed: 25312822 ( click the link to review the publication )
Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Toxicol Lett, 2014, 226(1):81-9

PubMed: 24495410 ( click the link to review the publication )

J Periodontal Res, 2014, 10.1111/jre.12193

PubMed: 24854880 ( click the link to review the publication )

PLoS One, 2014, 9(3):e85705

PubMed: 24633332 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87311

PubMed: 24489893 ( click the link to review the publication )

PLoS One, 2014, 9(5):e94753

PubMed: 24787138 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):167-72

PubMed: 24582558 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 64(2):180-90

PubMed: 24705173 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2014, Zhang JL

PubMed: ( click the link to review the publication )

Oncol Lett, 2014, 8(4):1739-1744

PubMed: 25202402 ( click the link to review the publication )

Hepatology, 2013, 59(4):1262-72

PubMed: 23929627 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

J Thromb Haemost, 2013, 12(3):395-408

PubMed: 24354620 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2013, 144PA:223-227

PubMed: 24514755 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 375(1-2):89-96

PubMed: 23707617 ( click the link to review the publication )

Cell Signal, 2013, 26(3):512-20

PubMed: 24308969 ( click the link to review the publication )

Microbes Infect, 2013, 15(2):105-14

PubMed: 23164610 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82610

PubMed: 24340049 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70732

PubMed: 23967093 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

PLoS One, 2013, 8(12):e85032

PubMed: 24376862 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63890

PubMed: 23667687 ( click the link to review the publication )
Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Atheroscler, 2011, 218(2):486-92

PubMed: 21782178 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features

Does not inhibit c-Raf phosphorylated MEK1.

Targets

MEK1 ^[1]
(Cell-free assay)

2 μM

In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. ^[1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. ^[2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. ^[3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H1355	Ml;0SpVv[3Srb36gRZN{[Xl?	MnX1NlUh\|ryP	M1PSRVEhcA>?		MUDicJVvfHNidHjlJGJc[V2SLXnu[JVk\WRiaX7jdoVie2ViaX6gdIhwe3Cqbz3DbIsyKGGwZDDwbI9{eGixLVXST{BmgHC{ZYPzbY9v	NXnrdVdpOjV5NkmxPFE>
MCF-7	MlfQSpVv[3Srb36gRZN{[Xl?	MojaNVAh\|ryP	MmG0NUBp		MUTpcohq[mm2czDJUE0yQC2nbnjhcoNm\CClZXzsJI1q\3KjdHnvci=>	NULMSmJvOjV5MkewNVE>
HepG2	MX\GeY5kfGmxbjDBd5NigQ>?	NHTx[XQyOCEQvF2=	NHzYUHk2KGh?		MlH3Zoxw[2u\|IIDoc5NxcG:{eXzheIVlKE2DUFvzJIlv\HWlZXSgZpkh\XixZ3Xuc5V{KFSJRj5OtlE>	M3HXblI2PTZyNEi4
HepG2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MViyNEDPxE1?	NYnQfYFFOjRiaB?=		MV7zeZBxemW\|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v	NWDZclRyOjV3NkC0PFg>
MDA-MB-231	M3TYdmZ2dmO2aX;uJGF{e2G7	MlLENlUh\|ryP	NF;ZRokzNTNiaB?=		MYrk[YNz\WG\|ZYOgdE1GWktzL{KgZY5lKFNzMEDBOEBmgHC{ZYPzbY9v	MViyOVU2PTh5NR?=
SW480	Ml3xSpVv[3Srb36gRZN{[Xl?	M3TVTlIxyqEQvF2=	MUGxxsBp		NFHl[oxz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGFVTjNicILveIVqdg>?	MXOyOVQ1PzhzNh?=
HCT-15	M1vU[WZ2dmO2aX;uJGF{e2G7		M3XVXVEhcA>?		NVfzeplW[XS2ZX71ZZRmeyCSR1WyMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzc8Li	NILxTVkzPTR\|MUSyOS=>
HCT-15	NHXQN21CeG:ydH;zbZMhSXO\|YYm=		MUixJIg>		MoLGZYJwdGm\|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	NFXjOoIzPTR\|MUSyOS=>
786-O	MojCRZBweHSxc3nzJGF{e2G7	NHPwRpI2OMLizszN	NUe5enE1OjRiaB?=		NGL3bGNxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=>	M2D2S\|I1PTB6NEe2
A498	MVLBdI9xfG:\|aYOgRZN{[Xl?	NXvBUphQPTEEoN88US=>	NYDpTHd6OjRiaB?=		NF\ERnBxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=>	NF\qcGQzPDVyOES3Oi=>
NHBE	MYnGeY5kfGmxbjDBd5NigQ>?	MoP3Nk8zOCEQvF2=	MlfYNkBp		NH:5VopifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC\|ZXPy[ZRqd25?	NEf3Nm0zPDR5OUWyOi=>
A375	NX\YbWtiS2WubDDJcpZie2mxbjDBd5NigQ>?	NUnRVmc5OTEkgKOyNEDDvU1?	NIe5XYQzPCCq		MnjEdoVlfWOnczDt[Yxidm:vYTDj[YxtKGmwdnHzbY9v	NGf5PGQzPDR4NkCzOi=>
HBMEC	NYqySVBCTnWwY4Tpc44hSXO\|YYm=	MXWxNEDPxE1?	NYLaU2hzOSCq		NUfZXmhx[myxY3vzJHZGT0ZvaX7keYNm\CCHcHjBNkBmgHC{ZYPzbY9v	M{eyPFI1PDV6OUiy
HPAEpiCs	MYLGeY5kfGmxbjDBd5NigQ>?	NVvtc4dNOzBizszN	NHLOcZYyKGh?		NWS0TW1ucW6qaXLpeJMhXE6ILd8xJJN1cW23bHH0[YQheDR{L4C0OEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?	NGH4OlMzPDR2MUi3NC=>
BeWo	NWTiU3JOTnWwY4Tpc44hSXO\|YYm=	NIXDSm4yOMLizszN	M{X5TFIhcA>?		NVnjOIFTcW6qaXLpeJMhTVKNMT:y	MkPoNlQ1OzN6NE[=
PC3	NGPPNmhCeG:ydH;zbZMhSXO\|YYm=	MkTXOVAh\|ryP	NIPkVlQxNjViaB?=		NVW2WJVRcW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:Kh	NYfNXYZFOjR2MkS4PFk>
HGC-27	M33XSmFxd3C2b4Ppd{BCe3OjeR?=	NYDRcFU4OSEEtV2=	MkL1NUBp		NVfwTWhCe3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:\|cx?=	MVqyOFQyPjN2OR?=
MCF-7	NILKNo9HfW6ldHnvckBCe3OjeR?=	NHSzW2YyOMLizszN	NITvOnkyOC9\|MDDtbY4>		Mn61doVlfWOnczD0bIUhXVSSLXTldIVv\GWwdDDFVmsheGixc4Doc5J6dGG2aX;u	MoWxNlQ{QTB6MUm=
HUVECs	NInWcWlHfW6ldHnvckBCe3OjeR?=	MkPpNVDDqM7:TR?=	M4rJOVEhcA>?		M1HFfIlvcGmkaYTzJJRp\SCKRFygdoVlfWOnZDDDU3guOiCneIDy[ZN{cW:wIHHu[EBRT0lvMjDy[Yxm[XOn	NHvwXFAzPDN6NUGwPS=>
HeLa	MnvSSpVv[3Srb36gRZN{[Xl?	MXG1NEDPxE1?	MXywMlUhcA>?		M4\JToJtd2OtczDUVnguOSCwdXPs[YFzKG2rZ4LheIlwdiCjbnSgWHhPUVBiZH;3ck1z\We3bHH0bY9v	NV7oVHVsOjR\|N{[4Nlc>
HL-60	M2LiOGZ2dmO2aX;uJGF{e2G7	MX:xNE8zOCEQvF2=	MVqxJIg>		M3nRZYlvcGmkaYTzJJRp\cLiTj6gZ4hqdmWwc3nz[Zh1emGldNMgbY5lfWOnZDDkbYZn\XKnboTpZZRqd25iaX70c{BoemGwdXzvZ5l1\XN?	NULUR5pYOjR\|NUewNlA>
HL-60	M4Gyd2Z2dmO2aX;uJGF{e2G7	M4T6bFIhyrWP	NVLZOYdlOTZiaB?=	MXTEUXNQ	M2rnNIlvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN\|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN\|	MnvTNlQ{OzByNki=
HEK 293	M1[wWGZ2dmO2aX;uJGF{e2G7	MnXhNVAh\|ryP	MlnlOUBp	NGf1NYFFVVOR	MV\pcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh\|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36=	NYToSWlQOjR\|MkSzOlY>
HEK 293	MYPGeY5kfGmxbjDBd5NigQ>?	M2Ww[\|ExKM7:TR?=	NWO1UIltPSCq	M17tW2ROW09?	MVjzeZBxemW\|c3XzJJRp\SCFUmSgZYN1cX[rdIm=	NXXO[I5IOjR\|MkSzOlY>
SW480	NEPMZodHfW6ldHnvckBCe3OjeR?=	NH3JN2gyOCEQvF2=	M3HTSVIxKGh?	M4PaNGROW09?	NHHIbZJ{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk>	NFLTVmUzPDN{NEO2Oi=>
HCSMCs	M2K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWxNEDPxE1?	M3PXN\|I1KGh?		NVLjTFJ[[myxY3vzJGZCSlB2LXnu[JVk\WRiSFPBV21EKHC{b3zp[oVz[XSrb36=	MX[yOFMyOjN6MR?=
PANC-1	MmDjSpVv[3Srb36gRZN{[Xl?	Mk\jNlAh\|ryP	MWe0PEBp		NFL5N3dqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kDPnD[GIHnuJJJme3CxboPlJJRwKHSqZTDQVGFT\|rUEoHHnc45qe3UEoB?=	NWPNdXp3OjR{OUSxN\|M>
A549	NGPs[WJHfW6ldHnvckBCe3OjeR?=	NFznbHc{OCEQvF2=	NGLLSFkxNjViaB?=	NF3YWZdFVVOR	MX7pcohq[mm2czD0bIUhfGi{b33ibY4ucW6mdXPl[EBKVC16L1PYR2w5NUy3YzDhZ5Rqfmm2eR?=	NH7MOoEzPDJ5N{[5Oi=>
A549	MXTGeY5kfGmxbjDBd5NigQ>?	NEHEd2k{OCEQvF2=	M17QeVAvPSCq	NX3QV2YxTE2VTx?=	NYGzTlFScW6qaXLpeJMhfGi{b33ibY4ucW6mdXPl[EBEN0WEUN8yJHRpejJ\|NdMgdIhwe3Cqb4L5cIF1cW:w	M1nQWVI1Ojd5Nkm2
MC-3	NI\3PGtCeG:ydH;zbZMhSXO\|YYm=	MYmxNEDPxE1?	NH;ST2szPCCq		MWrwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m\|IHnuJEBk\Wyucx?=	M2DBWFI1OjdyNUKz
Raji	Ml[zSpVv[3Srb36gRZN{[Xl?	MWGxNEDPxE1?	M2O5VlEhcA>?		MVTicI9kc3NiaIPCRWZHKGmwZIXj[YQhTXKtMT:yJJBpd3OyaH;yfYxifGmxbh?=	NGX3WZgzPDJ4OU[zNC=>
Raji	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojmNVAh\|ryP	NXLnOGFYOSCq		MX7pcohq[mm2czD0bIUh[mG\|YXygc5IhcHOEQV\GMZN1cW23bHH0[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdIm=	MYWyOFI3QTZ\|MB?=
HT29	NWPsbVVHTnWwY4Tpc44hSXO\|YYm=	NHLHbI4yOCEQvF2=	NFT4PWMzKGh?		NXPmOnBRcW6qaXLpeJMhd2ZiSlHLNkwhTVKNMT:yJIFv\CCVVFHUN{BxcG:\|cHjvdplt[XSrb36=	MmfyNlQzPjV{OUO=
HepG2	MoTHRZBweHSxc3nzJGF{e2G7	MoG2NlAh\|ryP	MnjSNlQhcA>?		MofYbY5pcWKrdIOgSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCjbnSg[Y5p[W6lZYOgWmIyNWmwZIXj[YQh[XCxcITvd4l{	NVnlVXNHOjR{NEe5NFk>
HepG2	NXfaNmNmTnWwY4Tpc44hSXO\|YYm=	M1rWblIxKM7:TR?=	M2\i[lIhcA>?		M1nnTIVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm=	NIPGOZIzPDJ2N{mwPS=>
TE4	MXzGeY5kfGmxbjDBd5NigQ>?	MXKyNE82OC9zMECg{txO	MXG0PEBp	M1nrRWROW09?	MYHpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NXHHNIZvOjR{NESwNlM>
TE1	NHrVOFdHfW6ldHnvckBCe3OjeR?=	M2ixSlIxNzVyL{GwNEDPxE1?	M1XHdVQ5KGh?	NYPv[nhQTE2VTx?=	MV;pcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NHzmSI8zPDJ2NECyNy=>
KYSE30	M1:zSmZ2dmO2aX;uJGF{e2G7	M{LPSlIxNzVyL{GwNEDPxE1?	MX[0PEBp	NV;pNWFPTE2VTx?=	M3rKSIlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M3;yb\|I1OjR2MEKz
TE1	NYj2TYN[TnWwY4Tpc44hSXO\|YYm=	M{DSd\|UxKM7:TR?=	MWO0PEBp	MV\EUXNQ	MV71dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	MUSyOFI1PDB{Mx?=
TE3	NF;qc2lHfW6ldHnvckBCe3OjeR?=	NV64TXVwPTBizszN	MVK0PEBp	NE\yXGdFVVOR	MXj1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	NWrheWNOOjR{NESwNlM>
TE4	NIrLem1HfW6ldHnvckBCe3OjeR?=	NFHTN482OCEQvF2=	M1LPXVQ5KGh?	M4jWR2ROW09?	MmixeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	M3Hnb\|I1OjR2MEKz
TE5	NETIVWNHfW6ldHnvckBCe3OjeR?=	M1HuU\|UxKM7:TR?=	M1jsbFQ5KGh?	MoXrSG1UVw>?	NHTodFh2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	NETC[XIzPDJ2NECyNy=>
KYSE30	NUHWd2NxTnWwY4Tpc44hSXO\|YYm=	NXTiO5RbPTBizszN	NV3FZW1DPDhiaB?=	M3vrSmROW09?	MU\1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	MWSyOFI1PDB{Mx?=
MKN7	Ml7ZSpVv[3Srb36gRZN{[Xl?	NGnsUIc2OCEQvF2=	MojoOFghcA>?	NVvuV3ByTE2VTx?=	Ml3HbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	NEDBN5YzPDJ2NECyNy=>
OE19	MWrGeY5kfGmxbjDBd5NigQ>?	NGfESlY2OCEQvF2=	MX20PEBp	M372cWROW09?	MnPPbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	NYDXXoNuOjR{NESwNlM>
KATOIII	NY\GW2ZoTnWwY4Tpc44hSXO\|YYm=	MnO3OVAh\|ryP	NGDYSpI1QCCq	MVfEUXNQ	NVrtO2ZOcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NYDLU\|Q{OjR{NESwNlM>
NCI-N87	MU\GeY5kfGmxbjDBd5NigQ>?	MXu1NEDPxE1?	MYW0PEBp	MXTEUXNQ	MoS1bY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	NID5c24zPDJ2NECyNy=>
NUGC3	M13sS2Z2dmO2aX;uJGF{e2G7	M2r5XFUxKM7:TR?=	M{HLPFQ5KGh?	NE\zXW9FVVOR	M1f0TIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=	NHz6d5AzPDJ2NECyNy=>
NUGC2	MXLGeY5kfGmxbjDBd5NigQ>?	MXK1NEDPxE1?	MYK0PEBp	MXfEUXNQ	NFHhXoJqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	M{TzU\|I1OjR2MEKz
SGC-7901	MkXDRZBweHSxc3nzJGF{e2G7	NE\KXYQzOCEQvF2=	MlO1NlQhcA>?		NFv5WXlqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN?	MVKyOFI1OTN3MR?=
MG-63	MX7GeY5kfGmxbjDBd5NigQ>?	M33UOVIxKM7:TR?=	MV6wMlUhcA>?		NHfIS5hjdG:la4OgeIhmKEOKLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQhTUyNMTDwdo91\WmwIHX4dJJme3Orb36=	NWi0[mZCOjR{M{m2OFA>
ARPE-19	MXLGeY5kfGmxbjDBd5NigQ>?	MV[yNEDPxE1?	NHjFdosxNjViaB?=		MmPQbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	MX2yOFIzPzlzOB?=
CRL-2302	M3HjTWZ2dmO2aX;uJGF{e2G7	MVeyNEDPxE1?	MUewMlUhcA>?		M1L5bIlvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=>	M4jMS\|I1OjJ5OUG4
MCF-7	NHzDN4VHfW6ldHnvckBCe3OjeR?=	NF3Jd5gzOCEQvF2=	NITWRokyKGh?		MVXhZo9tcXOqZYOg[ZhxemW\|c3nvckBw\iCyaH;zdIhwenmuYYTl[EBGWktiY3:teJJm[XSvZX70JJdqfGhiY3;ubpVo[XSn	M2X0TVI1OjF4Mki5
MCF-7	MlHsRZBweHSxc3nzJGF{e2G7	M2TkXlIxKM7:TR?=	NXHQNW5qOSCq		NXvNd21vcW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk>	NHzYcmQzPDJzNkK4PS=>
DLD-1	M4fBXGZ2dmO2aX;uJGF{e2G7	NHrwPGozOMLizszN	M4Owc\|Q5KGh?		MoTldoVlfWOnczD0bIUhSk6LUEOg[ZhxemW\|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD	M4nBV\|I1OjFzNUix
HT-29	M{XFUmZ2dmO2aX;uJGF{e2G7	NUfQenBVOjEEoN88US=>	Mny2OFghcA>?		MXLy[YR2[2W\|IITo[UBDVkmSMzDlfJBz\XO\|aX;uJJBz\S22cnXheIVlKHerdHigOU1igmFvZFO=	MlrXNlQzOTF3OEG=
7402	NFqxdHdCeG:ydH;zbZMhSXO\|YYm=	NV;3U3FCOzBizszN	NYO5N4p4PSCm		NWfzZVRo\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>?	MnjINlQzOTF{NUO=
7721	M1;ONmFxd3C2b4Ppd{BCe3OjeR?=	MUizNEDPxE1?	M2PnS\|Uh\A>?		M{LX[IRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44>	Ml;6NlQzOTF{NUO=
SGC7901	NVfaUmNmSXCxcITvd4l{KEG\|c3H5	NXzlUm5jPTEEoN88US=>	MlLsNlQwPDhxN{KgbC=>	MU\EUXNQ	NGm1eGFqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT\|Ihe2iUTlG=	MUmyOFE4QDJ2MB?=
SMMC7721	MWTGeY5kfGmxbjDBd5NigQ>?	NHfjPHYzPS93MDFOwG0>	NXLKO5V[OjRiaB?=		MUXzeZBxemW\|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA>	M1HVTVI1OTZ6MEW2
MCF-7	NHi1OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWyNVAh\|ryP	MkPUOFhp	MUPEUXNQ	M2DYUJJmfmW{c3XzJGJPTi2rbnT1Z4VlKGOnbHygZ5lkdGViYYLy[ZN1	MXqyOFE3OzRyNB?=
Caco-2	M33pUGZ2dmO2aX;uJGF{e2G7	NIHxbI02OMLizszN	NIL4V2Y1QGh?	MoLmSG1UVw>?	NH3uOXRmdmijbnPld{B1cGVibWLORUBt\X[nbIOgc4bDqFOFTl6xRUxHYFmGMz\|CpGxEXC{EoFzPXEzDqEiLRkPBMOKhYkdzNj\|CpHBFTT[DwrDhcoTDqEyJQVzTNVbDqGenbnXzxsBkdy22cnXheIVlKHerdHigSIV5	NUTqUFNSOjRzNkG2PVU>
HAECs	MWjGeY5kfGmxbjDBd5NigQ>?	NI\rfXoyOCEQvF2=	M4\uPFEhcA>?		MnzSxsBifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKEmFQV2tNUBidmRiVlPBUU0yKGW6cILld5Nqd25?	MVOyOFE{PDZ3Nx?=
Ca9-22	NFv6bZJHfW6ldHnvckBCe3OjeR?=	NVrtNoFwOyEQvF2=	MlvmNUBp		NXjSR2p{[WKxbHnzbIV{KHSqZTDhZoltcXS7IH;mJGhjWiC2bzDpcoR2[2ViSVytPEBxem:mdXP0bY9v	Mln2NlQyOjZ3M{K=
Ca9-22	M37oPGZ2dmO2aX;uJGF{e2G7	Mn7qN{DPxE1?	MWSxM\|IhcA>?		MXHy[YR2[2W\|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>?	NWrSOnJlOjRzMk[1N\|I>
AGS	NVLibog{TnWwY4Tpc44hSXO\|YYm=	NILjZmsyOCEQvF5CpC=>	MWiwMlUhcA>?		MoKxbY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n	Mn;0NlQyODZzNk[=
Caco-2	NXPjfYhFSXCxcITvd4l{KEG\|c3H5	M4Wyc\|ExyqEQvF2=	M363OlI1yqCq		M2LZW4Rm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV?	MUeyOFA6PTh4Mx?=
HCT-8	MYfBdI9xfG:\|aYOgRZN{[Xl?	NXvvUoN1OTEEoN88US=>	NGO2bHMzPMLiaB?=		M{DafoRm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV?	NGT1SYMzPDB7NUi2Ny=>
A549	NWjrbYdSTnWwY4Tpc44hSXO\|YYm=	NXLleFhsPTEEoN88US=>	NGLZOoszKGh?		M{jsTYJtd2OtczDFVmsheGixc4Doc5J6dGG2aX;uJI1m\GmjdHXkJIJ6KDFuMj3OVS=>	NVewS2lLOjRyNke3Nlc>
HPMC	MlGzSpVv[3Srb36gRZN{[Xl?	NFPSZpgyOMLizszN	MnnSOFghcA>?		MYjy[ZZmenOnczD0bIUh[2ijbnfld{BqdiClZXzsJI1wenCqb3zv[5khcW6mdXPl[EBjgSCKR2DEVy=>	M3vVWVI1ODR{OEO4
HPMC	M4X2S2Fxd3C2b4Ppd{BCe3OjeR?=	MUmxNOKh\|ryP	NXjVSmdUOjUEoHi=		NF7wW5Fz\X[ncoPld{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KEiJUFTT	M2Tse\|I1ODR{OEO4
MGC803	NEGxOmRCeG:ydH;zbZMhSXO\|YYm=	MUWyNOKh\|ryP	MoXPNUBp		MmDybY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU	M4XZclI1ODJ5N{Ww
SGC7901	M1nrdWFxd3C2b4Ppd{BCe3OjeR?=	M1jGOFIxyqEQvF2=	MVWxJIg>		M{fuUYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=	NXP3Vmk5OjRyMke3OVA>
COLO205	MkTKRZBweHSxc3nzJGF{e2G7	NET1RXYyOC9{MD:0NEDPxE1?	M{HO[FI1KGh?		MXvpcoR2[2W\|IFTORUBt[WSmZYKg[o9zdWG2aX;u	MYWyOFAyQTFyOB?=
G292	M4ToVWFxd3C2b4Ppd{BCe3OjeR?=	MnfWN\|DDqM7:TR?=	NE\o[pYzKGh?		MXXy[ZN1d3KnczDjZZB{[WmlaX6tbY5lfWOnZDDj[YxtKGSnYYTo	NHexeHQzPDBzMkmzNC=>
BxPC-3	MkLqSpVv[3Srb36gRZN{[Xl?	MnLPNVAh\|ryPwrC=	NVzWOGQxPiCq		MlTRbY5kemWjc3WgcYlTNTF2MzDlfJBz\XO\|aX;u	M{P2fFI{QTd\|N{Gw
HPAF-II	MoLHSpVv[3Srb36gRZN{[Xl?	MXWxNEDPxE4EoB?=	M3zkS\|YhcA>?		MWTpcoNz\WG\|ZTDtbXIuOTR\|IHX4dJJme3Orb36=	M3fiOlI{QTd\|N{Gw
HL-60	MX\BdI9xfG:\|aYOgRZN{[Xl?	M1GzXlUxyqEQvF2=	NXqwNFZGOSCq		NYr2TXhiemW\|Y4Xld{BDSTF2NTDt[YRq[XSnZDDhdI9xfG:\|aYO=	Ml3GNlM6PDh5NUG=
HepG2	M2n3R2Z2dmO2aX;uJGF{e2G7	MW[0NEDPxE1?	NUL2XIxsPi9zMjDo		MWrpcohq[mm2czD0bIUhcW6lcnXhd4Uhd2ZicD3FVmsyKGGwZDDwMYMuUnWwIIDyc5RmcW5iZYjwdoV{e2mxbjDifUBRVA>?	NV61fIJIOjN7NEK4OVE>
HUVECs	Mom4SpVv[3Srb36gRZN{[Xl?	MXuyOUDPxE1?	NXjseFlJOSCq		NEm1S2RqdmO{ZXHz[UBPTi4QulKgdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbh?=	M3TreFI{QTBzMEC4
LNCaP	MmP2SpVv[3Srb36gRZN{[Xl?	MYqxNEDPxE4EoB?=	NXXHTVd1OSCq		Ml\J[IVkemWjc3XzJJRp\SCHR1[geZBz\We3bHH0[YQheC2\Qj2x	NH3j[28zOzh\|OEOxPC=>
HL60	M3nDUmZ2dmO2aX;uJGF{e2G7	NYm2WmNDOjEEoN88US=>	M4\hflczKGh?	NWnqfWx7TE2VTx?=	MVzpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w	MoPENlM5OjV3OEW=
NB4	MYXGeY5kfGmxbjDBd5NigQ>?	MXqxNEDPxE4EoB?=	M4\qS\|czKGh?	MXPEUXNQ	NX6wWYJvcW6qaXLpeJMh\GG\|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW\|c3nvci=>	M1HEVlI{QDJ3NUi1
EPOR/CR3	NHHONZNHfW6ldHnvckBCe3OjeR?=	MXi1NOKh\|ryP	NGXUR2c{KGh?		MlPpdoVlfWOnczDFVG8h[W6mL3;yJGlNNTNvaX7keYNm\CC2aHWgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wwrC=	M3ju[FI{QDJyN{Ox
HUASMCs	NH2wTpFHfW6ldHnvckBCe3OjeR?=	NWPJWXV{OTBizszNxsA>	NXfLNHRROjRiaB?=		NEniNpdlcW2rbnnzbIV{KEGwZzDJTU1k[XW\|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC=	M4e5TVI{QDF4NE[4
HUASMCs	NHi1O5ZHfW6ldHnvckBCe3OjeR?=	NWq1NYpNOTBizszNxsA>	NH7KTVYzPCCq		MoDHbY5pcWKrdIOgRY5oKEmLLXnu[JVk\WRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBt\X[nbB?=	MYKyN\|gyPjR4OB?=
SGC7901	MX3GeY5kfGmxbjDBd5NigQ>?	NXu3dXI3OTBizszNxsA>	M333OlI1KGh?		NIrBZnBqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:\|cHjvdplt[XSnZDDFVmsyNzJ?	M3H4blI{Pzl{NUi4
MKN45	M2fHb2Z2dmO2aX;uJGF{e2G7	M122TVExKM7:TdMg	MV6yOEBp		M{HiO4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	M1y0TFI{Pzl{NUi4
SGC7901	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[wVFExKM7:TdMg	MXeyOE81QC95MjDo		NYTxS\|NXcW6qaXLpeJMh[2WubDDndo94fGhiY3:teJJm[XSnZDD3bZRpKESDUGS=	MX2yN\|c6OjV6OB?=
MKN45	NVLOSZlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSxNEDPxE4EoB?=	M37meVI1NzR6L{eyJIg>		NIfmeHBqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?=	NGjHcIszOzd7MkW4PC=>
SGC7901	NXXoVoxESXCxcITvd4l{KEG\|c3H5	NX3DU2s4OTBizszNxsA>	M4rnVlI1KGh?		MoHrbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?	MnvnNlM4QTJ3OEi=
MKN45	NX7LVGZySXCxcITvd4l{KEG\|c3H5	NFSzWWcyOCEQvF5CpC=>	NHGyZ3ozPCCq		MnrwbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?	MmDENlM4QTJ3OEi=
BxPC-3 cells	M3T6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr5RWszOMLizszN	MU[wMlUhcA>?		MkTMbY5pcWKrdIOgWmVITi2DLYLl[5Vt[XSnZDDIWXZGSyCpcn;3eIgh[W6mIIT1ZoUh\m:{bXH0bY9vKGmwZIXj[YQh[nliUFHSMVIhSVB?	M1PwcFI{PzZ2MES2
NB4	NH\RWpdCeG:ydH;zbZMhSXO\|YYm=	M{e1bVExNzJyL{[wJO69VQ>?	M2HGVVEvPSCq	MVXEUXNQ	NYHmZnR[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDQZYNtcXSjeHXs	MmfQNlM4OzV3NEG=
HepG2	NGLWNpBHfW6ldHnvckBCe3OjeR?=	MkizNlDDqM7:TR?=	MmXENlQhcA>?		NWLnSWxRcW6qaXLpeJMhfGinIFjPMVEheHKxdHXpckBmgHC{ZYPzbY9vKGOxLYTy[YF1\WRid3n0bEBu\XSob4LtbY4>	NWnKS4tZOjN5MEe2NFk>
HUVECs	MYHBdI9xfG:\|aYOgRZN{[Xl?	MmHaNk81KM7:TR?=	MmrENlQwPDhiaB?=		MnTjbY5lfWOnczDj[YxtKGSnYYTo	NV\1WIF1OjN5MEe1NlA>
KG-1	MnflRZBweHSxc3nzJGF{e2G7	NGXCOFIzOMLizszN	NYLRNodHOTJiaB?=		MkPS[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=>	M{HrWlI{PzB4Nkmx
AML 1#	NUPMXFljSXCxcITvd4l{KEG\|c3H5	NE\JPG0zOMLizszN	MWWxNkBp		MWPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx	MVqyN\|cxPjZ7MR?=
A2780	Mo\4SpVv[3Srb36gRZN{[Xl?	NEDISFgzOMLizszN	NYX2dW5zOSCq		M3\keYJtd2OtczDEWGNFNWmwZIXj[YQhTFJ3IHX4dJJme3Orb36=	NXmweVFbOjN4OU[4OlI>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; PubMed: 17482134 Cancer cell ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-JNK / JNK / Cyclin D1 ; PubMed: 17482134 Cancer cell Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-HER2 / HER2 ; PubMed: 24244023 J Immunol TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. MMP9 / XIAP / VEGF ; PubMed: 29695559 In Vivo SK-Hep1 cells were treated 10 μM PD98059 for 48 h. Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.	17482134 24244023 29695559

In vivo

Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. ^[5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. ^[6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. ^[7]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro MEK-inhibitory activity: Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research: ^[1]	+ Expand Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562 Concentrations: Dissolved in DMSO, final concentrations ~100 μM Incubation Time: 3 dyas, or 7-10 days Method: For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope. (Only for Reference)
Animal Research: ^[7]	+ Expand Animal Models: Male Sprague–Dawley rats with acute pancreatitis Formulation: Dissolved in DMSO, and diluted in saline Dosages: 10 mg/kg Administration: Injection i.v. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD98059 SDF

Molecular Weight	267.28
Formula	C₁₆H₁₃NO₃
CAS No.	167869-21-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to formulate this inhibitor for i.p. injection?
Answer:
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Pan MEK Inhibitor

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM.
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products4

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD98059

Cited by 128 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD98059 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

PD98059

Cited by 128 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD98059 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)